Anaphylaxis ≈ Anaphylaxis
View article
World Allergy Organization Anaphylaxis Guidance 2020 Open
Anaphylaxis is the most severe clinical presentation of acute systemic allergic reactions. The occurrence of anaphylaxis has increased in recent years, and subsequently, there is a need to continue disseminating knowledge on the diagnosis …
View article
Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals Open
Conjugation of polyethylene glycols (PEGs) to proteins or drug delivery nanosystems is a widely accepted method to increase the therapeutic index of complex nano-biopharmaceuticals. Nevertheless, these drugs and agents are often immunogeni…
View article
EAACI guidelines: Anaphylaxis (2021 update) Open
Anaphylaxis is a clinical emergency which all healthcare professionals need to be able to recognize and manage. The European Academy of Allergy and Clinical Immunology Anaphylaxis multidisciplinary Task Force has updated the 2014 guideline…
View article
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020 Open
As of January 3, 2021, a total of 20,346,372 cases of coronavirus disease 2019 (COVID-19) and 349,246 associated deaths have been reported in the United States. Long-term sequalae of COVID-19 over the course of a lifetime currently are unk…
View article
Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021 Open
This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the CDC in the first month of use of the Pfizer-BioNTech and Moderna COVID-19 vaccines in the US, December 14, 2020-January 18, 2021.
View article
Identification of a T follicular helper cell subset that drives anaphylactic IgE Open
Thirteen is the charm in anaphylaxis Immunoglobulin E (IgE) is a type of antibody associated with allergies and response to parasites such as worms. When high-affinity, allergen-specific IgE binds its target, it can cross-link receptors on…
View article
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine Open
This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the CDC in the first week of use of the Pfizer-BioNTech COVID-19 vaccine in the US, December 14-23, 2020.
View article
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021 Open
As of January 20, 2021, a total of 24,135,690 cases of coronavirus disease 2019 (COVID-19) and 400,306 associated deaths had been reported in the United States (https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days). On Dec…
View article
Increases in anaphylaxis fatalities in Australia from 1997 to 2013 Open
Summary Background Recent epidemiological studies indicate increases in Australian, UK and US hospital anaphylaxis admission rates. Objectives The aim of this study was to determine whether Australian anaphylaxis fatalities are increasing …
View article
The challenge of de‐labeling penicillin allergy Open
Background Even though 8%‐25% of most populations studied globally are labeled as penicillin allergic, most diagnoses of penicillin allergy are made in childhood and relate to events that are either not allergic in nature, are low risk for…
View article
Wheat allergy: diagnosis and management Open
Antonella Cianferoni Department of Pediatrics, Division of Allergy and Immunology, The Childrens Hospital of Philadelphia, PA, USA Abstract: Triticum aestivum (bread wheat) is the most widely grown crop worldwide. In genetically predispose…
View article
Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID‐19 vaccine Open
The authors declare no conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.
View article
Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry Open
Background Preventive measures to decrease the frequency and intensity of anaphylactic events are essential to provide optimal care for allergic patients. Aggravating factors may trigger or increase the severity of anaphylaxis and therefor…
View article
Japanese guidelines for allergic rhinitis 2017 Open
Like asthma and atopic dermatitis, allergic rhinitis is an allergic disease, but of the three, it is the only type I allergic disease. Allergic rhinitis includes pollinosis, which is intractable and reduces quality of life (QOL) when it be…
View article
Anaphylaxis: A 2023 practice parameter update Open
This practice parameter update focuses on 7 areas in which there are new evidence and new recommendations. Diagnostic criteria for anaphylaxis have been revised, and patterns of anaphylaxis are defined. Measurement of serum tryptase is imp…
View article
Food anaphylaxis in the United Kingdom: analysis of national data, 1998-2018 Open
Objective To describe time trends for hospital admissions due to food anaphylaxis in the United Kingdom over the past 20 years. Design Analysis of national data, 1998-2018. Setting Data relating to hospital admissions for anaphylaxis and d…
View article
Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions Open
Polyethylene glycol (PEG)-coated nanopharmaceuticals can cause mild to severe hypersensitivity reactions (HSRs), which can occasionally be life threatening or even lethal. The phenomenon represents an unsolved immune barrier to the use of …
View article
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab Open
Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations asso…
View article
Precision medicine in allergic disease—food allergy, drug allergy, and anaphylaxis— <span>PRACTALL</span> document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology Open
This consensus document summarizes the current knowledge on the potential for precision medicine in food allergy, drug allergy, and anaphylaxis under the auspices of the PRACTALL collaboration platform. PRACTALL is a joint effort of the Eu…
View article
COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee Open
Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization …
View article
Food‐induced fatal anaphylaxis: From epidemiological data to general prevention strategies Open
Summary Background Anaphylaxis hospitalizations are increasing in many countries, in particular for medication and food triggers in young children. Food‐related anaphylaxis remains an uncommon cause of death, but a significant proportion o…
View article
Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Contrast Media Open
The objective of these guidelines is to ensure efficient and effective clinical practice. The panel of experts who produced this consensus document developed a research protocol based on a review of the literature. The prevalence of allerg…
View article
Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines Open
Mortality from coronavirus disease 2019 (COVID-19) in populations at high risk, such as the elderly, certain ethnic groups (e.g., Black/African American, and Hispanic/Latino persons), obese individuals, and those with endothelial dysfuncti…
View article
An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis Open
Co-existence of drug-specific IgE and IgG antibodies aggravates neuromuscular-blocking agent-induced anaphylaxis in humans.
View article
The global burden of illness of peanut allergy: A comprehensive literature review Open
Peanut allergy (PA) currently affects approximately 2% of the general population of Western nations and may be increasing in prevalence. Patients with PA and their families/caregivers bear a considerable burden of self‐management to avoid …
View article
Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyond Open
Anaphylaxis is a severe, acute, life-threatening multisystem allergic reaction resulting from the release of a plethora of mediators from mast cells culminating in serious respiratory, cardiovascular and mucocutaneous manifestations that c…
View article
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines Open
The first approved COVID‐19 vaccines include Pfizer/BioNTech BNT162B2, Moderna mRNA‐1273 and AstraZeneca recombinant adenoviral ChAdOx1‐S. Soon after approval, severe allergic reactions to the mRNA‐based vaccines that resolved after treatm…
View article
Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers Open
Anaphylaxis is the most serious of all allergic reactions and can be fatal. The diagnosis is frequently delayed, and misdiagnosis often occurs with asthma or urticaria. Biomarkers such as tryptase are not routinely checked, and appropriate…
View article
The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders Open
Leukotrienes (LTs) are lipid mediators that play pivotal roles in acute and chronic inflammation and allergic diseases. They exert their biological effects by binding to specific G-protein-coupled receptors. Each LT receptor subtype exhibi…
View article
Vaccination and allergy: <span>EAACI</span> position paper, practical aspects Open
Immunization is highly effective in preventing infectious diseases and therefore an indispensable public health measure. Allergic patients deserve access to the same publicly recommended immunizations as non‐allergic patients unless risks …